Generex Biotechnology Completes Acquisition of Olaregen Therapeutix Inc.
January 08, 2019 13:29 ET
|
Generex Biotechnology Corp.
- Closes transaction to complete 51% acquisition of Olaregen Therapeutix - Plans Commercial Launch of FDA-cleared Excellagen® MIRAMAR, Fla., Jan. 08, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE --...
Generex Biotechnology Introduces Treatment Alternative to $6 Billion Ulcerative Colitis Surgery Market
January 07, 2019 15:42 ET
|
Generex Biotechnology Corp.
Announces closing of 51% acquisition of regenerative medicine company Regentys™Regentys Extracellular Matrix Hydrogel for the Treatment of Ulcerative Colitis and Other Inflammatory Bowel Diseases ...
GNBT – Generex Biotechnology Plans Breast Cancer Vaccine Spinout and Dividend
January 04, 2019 11:59 ET
|
Generex Biotechnology Corp.
Generex Biotechnology Provides Update on NuGenerex Immuno-Oncology Update on AE37 Clinical Trial NuGenerex Immuno-Oncology Spin Out and Stock Dividend MIRAMAR, Fla., Jan. 04, 2019 (GLOBE...
UPDATE -- Generex Biotechnology Makes Major Advance On $22 Billion Wound Care Market Announcing Milestone Agreement
January 03, 2019 17:39 ET
|
Generex Biotechnology Corp.
Generex Biotechnology Partner Olaregen Therapeutix Inc. Signs Manufacturing Agreements for Excellagen® Wound Healing Collagen Matrix Collagen Solutions & Berkshire Sterile Manufacturing to Supply...
Generex Biotechnology Makes Major Advance On $22 Billion Wound Care Market Announcing Milestone Agreement
January 03, 2019 11:49 ET
|
Generex Biotechnology Corp.
Generex Biotechnology Partner Olaregen Therapeutix Inc. Signs Manufacturing Agreements for Excellagen® Wound Healing Collagen Matrix Collagen Solutions & Berkshire Sterile Manufacturing to Supply...
GNBT - Goldman Small Cap Research Issues Research Report on Generex Biotechnology Corp. and Interview with its CEO
November 05, 2018 11:30 ET
|
Generex Biotechnology Corp.
BALTIMORE, Nov. 05, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Generex Biotechnology Corp. (GNBT), an emerging, diversified health care provider, announced today that Goldman Small Cap Research, a...
![Generex Biotechnology Corp. Logo](/news-release/logo/216771/0/216771.jpg?lastModified=12%2F09%2F2016%2022%3A59%3A49&size=2)
Generex Oncology Announces Consultancy of Dr. George E. Peoples, MD
September 02, 2010 09:30 ET
|
Generex Biotechnology Corp.
WORCESTER, Mass., Sept. 2, 2010 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (www.generex.com) (Nasdaq:GNBT) today announced the engagement of Dr. George E. Peoples, Jr., M.D., F.A.C.S. as a...
![Generex Biotechnology Corp. Logo](/news-release/logo/216771/0/216771.jpg?lastModified=12%2F09%2F2016%2022%3A59%3A49&size=2)
Generex Biotechnology Initiates Social Media Campaign for Its Corporate and e-Commerce Websites
September 01, 2010 09:30 ET
|
Generex Biotechnology Corp.
WORCESTER, Mass., Sept. 1, 2010 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (Nasdaq:GNBT), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, announced...
![Generex Biotechnology Corp. Logo](/news-release/logo/216771/0/216771.jpg?lastModified=12%2F09%2F2016%2022%3A59%3A49&size=2)
Generex Informs Stockholders of Minimum Exchange Ratio for Reverse Stock Split Proposal to be Considered at the Special Meeting of Stockholders on September 17, 2010
August 27, 2010 16:30 ET
|
Generex Biotechnology Corp.
WORCESTER, Mass., Aug. 27, 2010 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (Nasdaq:GNBT) (www.generex.com), the leader in drug delivery for metabolic diseases through the inner lining of...
![Generex Biotechnology Corp. Logo](/news-release/logo/216771/0/216771.jpg?lastModified=12%2F09%2F2016%2022%3A59%3A49&size=2)
Generex Oncology Names Dr. Craig Eagle to Its Scientific Advisory Board to Assist With Its Proprietary Cancer Vaccines Program
August 05, 2010 09:30 ET
|
Generex Biotechnology Corp.
WORCESTER, Mass., Aug. 5, 2010 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (Nasdaq:GNBT) (www.generex.com/">www.generex.com) announced today that it has named Craig Eagle, M.D. to its...